Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia

Podobne knjige/članki

• Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations
  od: Samah Alimam, et al.
  Izdano: (2018-06-01)
• P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
  od: P. Harrington, et al.
  Izdano: (2022-06-01)
• Bone marrow niche dysregulation in myeloproliferative neoplasms
  od: Natalia Curto-Garcia, et al.
  Izdano: (2020-05-01)
• Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review
  od: Jean-Christophe Ianotto, et al.
  Izdano: (2019-08-01)
• Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia
  od: Arief S. Gunawan, et al.
  Izdano: (2017-06-01)